1. Home
  2. PLBY vs GANX Comparison

PLBY vs GANX Comparison

Compare PLBY & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.93

Market Cap

159.5M

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.59

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
GANX
Founded
1953
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
159.5M
159.2M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PLBY
GANX
Price
$1.93
$2.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$3.00
$8.00
AVG Volume (30 Days)
1.9M
592.8K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
58.89
47.95
EPS
N/A
N/A
Revenue
$116,135,000.00
$55,180.00
Revenue This Year
$4.97
N/A
Revenue Next Year
$8.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$1.41
52 Week High
$2.75
$4.34

Technical Indicators

Market Signals
Indicator
PLBY
GANX
Relative Strength Index (RSI) 48.65 64.25
Support Level $1.53 $1.56
Resistance Level $2.64 $3.06
Average True Range (ATR) 0.26 0.18
MACD -0.01 0.13
Stochastic Oscillator 8.84 82.59

Price Performance

Historical Comparison
PLBY
GANX

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: